GCM
ADAP

Graham Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Graham Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-87,274
Closed -$17.2K – 1271
2025
Q1 		$17.2K Buy
87,274
+50,079
+135% +$25.9K ﹤0.01% 1248
2024
Q4 		$20K Buy
37,195
+24,603
+195% +$17.9K ﹤0.01% 1198
2024
Q3 		$12K Buy
+12,592
New +$14.3K ﹤0.01% 1067

Other funds holding ADAP

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Graham Capital Management's ADAP Position: Q2 2025 in Review

Graham Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q2 2025, closing a stake of 87,274 shares — an estimated $17.2K sold.

Graham Capital Management first reported a position in ADAP in Q3 2024 and held it in 3 quarters. The position peaked at $20K in Q4 2024. 65 funds tracked by Wall St. Rank hold ADAP as of Q2 2025.

  • Graham Capital Management reported no remaining Adaptimmune Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 87,274 Adaptimmune Therapeutics shares in Q2 2025, an estimated $17.2K.
  • Graham Capital Management first reported a position in Adaptimmune Therapeutics in Q3 2024 and held it in 3 quarters.
  • Graham Capital Management's Adaptimmune Therapeutics position peaked at $20K in Q4 2024.
  • 65 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.